[go: up one dir, main page]

BRPI0717156B8 - inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende - Google Patents

inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende

Info

Publication number
BRPI0717156B8
BRPI0717156B8 BRPI0717156A BRPI0717156A BRPI0717156B8 BR PI0717156 B8 BRPI0717156 B8 BR PI0717156B8 BR PI0717156 A BRPI0717156 A BR PI0717156A BR PI0717156 A BRPI0717156 A BR PI0717156A BR PI0717156 B8 BRPI0717156 B8 BR PI0717156B8
Authority
BR
Brazil
Prior art keywords
inhibitors
transporter
pharmaceutical composition
sodium glucose
sodium
Prior art date
Application number
BRPI0717156A
Other languages
English (en)
Inventor
A Harrison Bryce
B Rawlins David
C Goodwin Nicole
Mabon Ross
David Kimball S
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of BRPI0717156A2 publication Critical patent/BRPI0717156A2/pt
Publication of BRPI0717156B1 publication Critical patent/BRPI0717156B1/pt
Publication of BRPI0717156B8 publication Critical patent/BRPI0717156B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

inibidores do co-transportador 2 da glicose de sódio e métodos para o seu uso. a presente invenção refere-se a compostos e composições farmacêuticas compreendendo-os são divulgados os quais podem ser úteis para o tratamento de doenças e distúrbios tais como diabetes e obesidade.
BRPI0717156A 2006-09-29 2007-09-27 inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende BRPI0717156B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US84815606P 2006-09-29 2006-09-29
US60/848,156 2006-09-29
US90571407P 2007-03-08 2007-03-08
US60/905,714 2007-03-08
US94878007P 2007-07-10 2007-07-10
US60/948,780 2007-07-10
PCT/US2007/079654 WO2008042688A2 (en) 2006-09-29 2007-09-27 Phlorizin analogs as inhibitors of sodium glucose co-transporter 2

Publications (3)

Publication Number Publication Date
BRPI0717156A2 BRPI0717156A2 (pt) 2013-10-15
BRPI0717156B1 BRPI0717156B1 (pt) 2020-06-30
BRPI0717156B8 true BRPI0717156B8 (pt) 2021-05-25

Family

ID=38947681

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717156A BRPI0717156B8 (pt) 2006-09-29 2007-09-27 inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende

Country Status (24)

Country Link
US (5) US7781577B2 (pt)
EP (2) EP2308841B1 (pt)
JP (3) JP5283625B2 (pt)
KR (2) KR101492277B1 (pt)
AR (1) AR063047A1 (pt)
AT (1) ATE496888T1 (pt)
AU (1) AU2007304971B2 (pt)
BR (1) BRPI0717156B8 (pt)
CA (1) CA2664688C (pt)
DE (1) DE602007012292D1 (pt)
DK (2) DK2089361T5 (pt)
EA (1) EA016511B1 (pt)
ES (1) ES2477216T3 (pt)
FR (1) FR19C1053I2 (pt)
HU (1) HUS1900038I1 (pt)
IL (1) IL197836A (pt)
MX (1) MX2009003305A (pt)
NL (1) NL301003I2 (pt)
NO (1) NO345139B1 (pt)
NZ (1) NZ575811A (pt)
PL (2) PL2089361T4 (pt)
PT (2) PT2089361E (pt)
TW (1) TWI499414B (pt)
WO (1) WO2008042688A2 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
JP5653213B2 (ja) * 2007-07-26 2015-01-14 レクシコン ファーマシューティカルズ インコーポレイテッド ナトリウム・グルコース共輸送体２阻害剤の調製に有用な方法及び化合物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
RU2509773C2 (ru) 2008-07-15 2014-03-20 Теракос, Инк. Дейтерированные бензилбензольные производные и способы применения
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
KR101426180B1 (ko) 2009-11-02 2014-07-31 화이자 인코포레이티드 디옥사-비시클로［3.2.1］옥탄-2,3,4-트리올 유도체
WO2011070592A2 (en) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012025857A1 (en) * 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
CN103596564B (zh) 2011-06-01 2016-05-04 株式会社绿十字 作为sglt2抑制剂的二苯基甲烷衍生物
WO2012163990A1 (en) 2011-06-03 2012-12-06 Boehringer Ingelheim International Gmbh Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
US20140228303A1 (en) * 2011-06-13 2014-08-14 Panacea Biotec Ltd Novel sglt inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2014530186A (ja) 2011-09-13 2014-11-17 パナセア バイオテック リミテッド 新規ｓｇｌｔ阻害剤
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013348233C1 (en) * 2012-11-20 2018-09-06 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1
ES2694110T3 (es) 2013-02-04 2018-12-18 Taisho Pharmaceutical Co., Ltd. Fármaco profiláctico o terapéutico para el estreñimiento
CN103073606B (zh) * 2013-02-05 2016-05-18 中国医药研究开发中心有限公司 5’-s-(4,4’-二甲氧基三苯甲基)-2’-脱氧肌苷的合成与制备方法
PT2981269T (pt) * 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
CN111494357A (zh) 2013-12-17 2020-08-07 勃林格殷格翰动物保健有限公司 猫科动物中代谢紊乱的治疗
ES2712860T3 (es) 2014-01-23 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabólicos en animales caninos
FI3721882T3 (fi) 2014-04-01 2024-09-24 Boehringer Ingelheim Vetmedica Gmbh Aineenvaihduntahäiriöiden hoito hevoseläimissä
EP3197429B1 (en) 2014-09-25 2024-05-22 Boehringer Ingelheim Vetmedica GmbH Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
BR112018003749B1 (pt) 2015-08-27 2023-10-31 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas líquidas compreendendo inibidores sglt-2, kit de peças e processo para a produção da composição farmacêutica líquida
US10626135B2 (en) * 2016-05-25 2020-04-21 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof
EA201990951A1 (ru) 2016-10-19 2019-11-29 Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
WO2019134667A1 (zh) 2018-01-05 2019-07-11 南京明德新药研发股份有限公司 一种SGLTs抑制剂及其应用
WO2019166958A1 (en) * 2018-02-28 2019-09-06 Mylan Laboratories Ltd Process for the preparation of sotagliflozin
CN111989103A (zh) 2018-04-17 2020-11-24 勃林格殷格翰国际有限公司 药物组合物、其治疗方法和用途
WO2019215633A1 (en) * 2018-05-09 2019-11-14 Janssen Pharmaceutica Nv 5,5-difluoro- and 5-fluoro-5-methyl-c-glycoside derivatives useful as dual sglt1 / sglt2 modulators
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US12178809B2 (en) 2018-10-29 2024-12-31 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
US12213970B2 (en) 2018-10-29 2025-02-04 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
WO2020180647A1 (en) * 2019-03-01 2020-09-10 Lexicon Pharmaceuticals, Inc. Use of sotagliflozin for the treatment of patients with type 1 diabetes mellitus
WO2021004388A1 (zh) 2019-07-05 2021-01-14 山东丹红制药有限公司 一种SGLTs抑制剂的晶型及其应用
MX2022001044A (es) * 2019-07-26 2022-04-06 Medshine Discovery Inc Inhibidor de sglt2/dpp4 y su aplicacion.
CN114585358B (zh) 2019-07-26 2023-11-10 东宝紫星(杭州)生物医药有限公司 一种SGLTs/DPP4抑制剂及其应用
EP3771480A1 (en) * 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Continuous process for preparing the crystalline form ii of sotagliflozin
AU2020394498A1 (en) 2019-11-28 2022-06-09 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors in the drying-off of non-human mammals
KR20220143732A (ko) 2020-02-17 2022-10-25 베링거잉겔하임베트메디카게엠베하 고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
CN111763197A (zh) * 2020-07-08 2020-10-13 青岛大学 一种新型手性吲哚类化合物的合成方法
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
AU2022319909A1 (en) 2021-07-28 2024-02-22 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
JP2024525981A (ja) 2021-07-28 2024-07-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
US20230381101A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
TW202500160A (zh) 2023-03-06 2025-01-01 德商百靈佳殷格翰維美迪加股份有限公司 用於遞送特別是包含一或多種ｓｇｌｔ—２抑制劑之液體醫藥組合物之系統及方法
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
TW202508455A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
WO2025072413A1 (en) 2023-09-28 2025-04-03 Lexicon Pharmaceuticals, Inc. Methods of treating type 1 diabetes and kidney disease
WO2025076165A1 (en) 2023-10-06 2025-04-10 Lexicon Pharmaceuticals, Inc. Methods of reducing the risk of cardiovascular events in patients with left ventricular hypertrophy
WO2025160910A1 (en) * 2024-02-01 2025-08-07 New Wish Biotechnology Wuxi Co., Ltd. Indazole compound and pharmaceutical composition, preparation method and use thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870699A (en) * 1973-03-06 1975-03-11 Upjohn Co Lincomycin analogs
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
WO1995016049A1 (en) 1993-12-08 1995-06-15 The Scripps Research Institute Catalytic chemo-enzymatic asymmetric synthesis of carbohydrates
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
JP2885191B2 (ja) 1996-07-09 1999-04-19 日本電気株式会社 液晶プロジェクタ
JP3928197B2 (ja) 1997-01-23 2007-06-13 住友化学株式会社 アリール置換芳香族類の製造方法
US6664399B1 (en) 1999-09-02 2003-12-16 E. I. Du Pont De Nemours & Company Triazole linked carbohydrates
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
EP1270584B1 (en) 2000-03-17 2005-12-07 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US7053060B2 (en) 2000-11-30 2006-05-30 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
KR100701437B1 (ko) 2000-12-28 2007-03-30 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체 및 그 의약 용도
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
DE60209343T2 (de) 2001-04-11 2006-10-26 Bristol-Myers Squibb Co. Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
FR2826653B1 (fr) 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPWO2003011880A1 (ja) 2001-07-31 2004-11-18 キッセイ薬品工業株式会社 グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
CA2459172C (en) 2001-08-08 2011-07-05 Takeda Chemical Industries, Ltd. Bicyclic compound, production and use thereof
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
EP1432721A4 (en) 2001-09-13 2008-02-20 Bristol Myers Squibb Co PROCESS FOR THE PREPARATION OF REBECCAMYCIN AND ANALOGUE THEREOF
FR2831169B1 (fr) 2001-10-22 2003-12-12 Servier Lab Nouveaux derives d'hydroxyalkyle indolocarbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002361656A1 (en) 2001-12-14 2003-06-30 Purdue Research Foundation Enantiopure 4-deoxypentenosides, dihydropyrans and tetrahydropyrans and syntheses thereof
US6927294B1 (en) * 2002-03-08 2005-08-09 University Of Southern California Nitrogen-containing heterocycles
DE10213228A1 (de) 2002-03-25 2003-10-16 Bayer Ag Cyclopenten-Derivate
US6562791B1 (en) 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
BR0310006A (pt) * 2002-08-09 2005-02-15 Taisho Pharmaceutical Co Ltd Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
FR2845995A1 (fr) 2002-10-16 2004-04-23 Servier Lab Nouveaux derives de pyrrolo[3,4-c]carbazole et de pyrido[2,3-b]pyrrolo[3,4-e]indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2845996A1 (fr) 2002-10-16 2004-04-23 Servier Lab Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2507665A1 (en) 2002-12-04 2004-06-17 Kissei Pharmaceutical Co., Ltd. Preventive or remedy for diseases caused by hyperglycemia
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
CA2509835A1 (en) 2002-12-25 2004-07-15 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof
BR0317929A (pt) 2003-01-03 2006-04-11 Bristol Myers Squibb Co métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
WO2004080990A1 (ja) 2003-03-14 2004-09-23 Astellas Pharma Inc. Ｃ－グリコシド誘導体又はその塩
US7439232B2 (en) 2003-04-01 2008-10-21 Taisho Pharmaceutical Co., Ltd. Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
WO2004089966A1 (ja) 2003-04-01 2004-10-21 Taisho Pharmaceutical Co., Ltd. 選択的なヘテロアリール ５－チオ－β－Ｄ－アルドヘキソピラノシドの製造法
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
AR048377A1 (es) 2003-08-01 2006-04-26 Janssen Pharmaceutica Nv Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
CA2549025A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
EA010655B1 (ru) 2003-08-01 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индазол-о-глюкозиды
CA2549015A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic c-glycosides
JP4520988B2 (ja) 2003-08-26 2010-08-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシルオキシ−ピラゾール、これらの化合物を含む医薬組成物、これらの使用及びこれらの調製方法
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
CA2542077A1 (en) 2003-10-08 2005-04-21 President And Fellows Of Harvard College Pyrovalerone analogs and therapeutic uses thereof
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
DE102004017793A1 (de) 2004-02-21 2005-09-08 Biofrontera Discovery Gmbh Trioxacarcine und deren Verwendung
US20050197270A1 (en) 2004-02-24 2005-09-08 Novozymes A/S Enzyme stabilization in liquid detergents
WO2005085265A1 (ja) 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
JP4181605B2 (ja) 2004-03-16 2008-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
WO2006002233A2 (en) 2004-06-22 2006-01-05 Wall, Michael, A. Alvaradoins e-n, new antitumor and cytotoxic anthracenone g-glycosides
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2006005682A2 (en) 2004-07-08 2006-01-19 Ciba Specialty Chemicals Holding Inc. Preparation of alpha-hydroxy and alpha-amino ketones
US20070293690A1 (en) 2004-07-08 2007-12-20 Hiroshi Tomiyama Process for Production of Azulene Derivatives and Intermediates for the Synthesis of the Same
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP5010918B2 (ja) 2004-07-21 2012-08-29 キッセイ薬品工業株式会社 肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1773800A1 (de) 2004-07-27 2007-04-18 Boehringer Ingelheim International GmbH D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) * 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE102004046583A1 (de) 2004-09-23 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Xylopyranosyl-phenyl-substituierte Cyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004039096A1 (de) * 2004-08-11 2006-02-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Xylopyranosyl-phenyl-substituierte Cyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JP2008515821A (ja) 2004-10-06 2008-05-15 レセプトイコン・アンパルトセルスカブ 薬物誘発性細胞毒性の予防のための化合物の使用
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US7608594B2 (en) 2004-11-03 2009-10-27 University Of Kansas Novobiocin analogues as anticancer agents
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
ATE445608T1 (de) 2005-02-23 2009-10-15 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
WO2006104897A2 (en) 2005-03-25 2006-10-05 Inspire Pharmaceuticals, Inc. Cytoskeletal active compounds, composition and use
US20060240496A1 (en) 2005-04-21 2006-10-26 Lakshmi Anne Immunogens, derivatives and immunoassay for ethyl glucuronide
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
JP5175191B2 (ja) 2005-08-30 2013-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
US8253752B2 (en) 2006-07-20 2012-08-28 Qualcomm Incorporated Method and apparatus for encoder assisted pre-processing
AR064235A1 (es) 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US20080107744A1 (en) * 2006-11-06 2008-05-08 Jack Fa-De Chu Injectable hollow tissue filler
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
JP5653213B2 (ja) * 2007-07-26 2015-01-14 レクシコン ファーマシューティカルズ インコーポレイテッド ナトリウム・グルコース共輸送体２阻害剤の調製に有用な方法及び化合物
US8015005B2 (en) 2008-02-15 2011-09-06 Motorola Mobility, Inc. Method and apparatus for voice searching for stored content using uniterm discovery
TWI472521B (zh) * 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
AU2013348233C1 (en) * 2012-11-20 2018-09-06 Lexicon Pharmaceuticals, Inc. Inhibitors of sodium glucose cotransporter 1

Also Published As

Publication number Publication date
BRPI0717156A2 (pt) 2013-10-15
EA200970337A1 (ru) 2009-08-28
ATE496888T1 (de) 2011-02-15
EP2308841A2 (en) 2011-04-13
CA2664688C (en) 2015-03-17
JP5701845B2 (ja) 2015-04-15
CA2664688A1 (en) 2008-04-10
JP5283625B2 (ja) 2013-09-04
JP2015120736A (ja) 2015-07-02
DK2089361T5 (da) 2012-01-16
WO2008042688A3 (en) 2008-06-12
EP2308841B1 (en) 2014-04-16
EP2308841A3 (en) 2011-10-26
AU2007304971A1 (en) 2008-04-10
KR101492277B1 (ko) 2015-02-11
JP2010504998A (ja) 2010-02-18
PL2308841T3 (pl) 2014-09-30
MX2009003305A (es) 2009-05-28
BRPI0717156B1 (pt) 2020-06-30
AR063047A1 (es) 2008-12-23
PL2089361T3 (pl) 2011-06-30
NL301003I1 (pt) 2019-09-02
US8476413B2 (en) 2013-07-02
EP2089361B1 (en) 2011-01-26
US20190099436A1 (en) 2019-04-04
DK2308841T3 (da) 2014-06-30
KR20090061072A (ko) 2009-06-15
HUS1900038I1 (hu) 2019-09-30
WO2008042688A2 (en) 2008-04-10
ES2477216T3 (es) 2014-07-16
JP5889453B2 (ja) 2016-03-22
US20100311673A1 (en) 2010-12-09
US9365602B2 (en) 2016-06-14
PT2308841E (pt) 2014-06-11
KR20150002889A (ko) 2015-01-07
PL2089361T4 (pl) 2012-09-28
EP2089361A2 (en) 2009-08-19
NL301003I2 (nl) 2019-10-29
FR19C1053I2 (fr) 2020-04-03
US7781577B2 (en) 2010-08-24
EA016511B1 (ru) 2012-05-30
TW200826929A (en) 2008-07-01
DE602007012292D1 (de) 2011-03-10
US20140135277A1 (en) 2014-05-15
FR19C1053I1 (fr) 2019-11-15
IL197836A0 (en) 2009-12-24
JP2013079243A (ja) 2013-05-02
US20080113922A1 (en) 2008-05-15
NO20091700L (no) 2009-06-16
NO345139B1 (no) 2020-10-12
AU2007304971B2 (en) 2013-06-20
DK2089361T3 (da) 2011-04-18
TWI499414B (zh) 2015-09-11
IL197836A (en) 2014-01-30
NZ575811A (en) 2011-10-28
US20170087172A1 (en) 2017-03-30
PT2089361E (pt) 2011-05-02

Similar Documents

Publication Publication Date Title
BRPI0717156B8 (pt) inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
BRPI0918841B8 (pt) derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
BRPI0815708B8 (pt) composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
CR20110016A (es) Compuestos quimicos 251
BR112015011298A2 (pt) inibidores de cotransportador 1 de glicose de sódio
BRPI0821115A8 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
MX384206B (es) Formulaciones de inhibidores de dpp iv
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
BRPI0805826B8 (pt) compostos espiro-substituídos, composição farmacêutica e uso
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BRPI0909040B8 (pt) derivados de azetidina e ciclobutano, seus usos, e composição
BRPI0911273B8 (pt) composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
BRPI0707493B8 (pt) composto inibidor de enzimas e1 ativadoras e composição farmacêutica contendo o referido composto
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BRPI0507041A (pt) composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/06/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF